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Abstract
Background: The axonal tau protein is a tubulin-binding protein, which plays important roles in the formation
and stability of the microtubule. Mutations in the tau gene are associated with familial forms of frontotemporal
dementia with Parkinsonism linked to chromosome-17 (FTDP-17). Paired helical filaments of tau and extracellular
plaques containing beta-amyloid are found in the brain of Alzheimer’s disease (AD) patients.
Results: Transgenic models, including those of zebrafish, have been employed to elucidate the mechanisms by
which tau protein causes neurodegeneration. In this study, a transient expression system was established to
express GFP fusion proteins of zebrafish and human tau under the control of a neuron-specific HuC promoter.
Approximately ten neuronal cells expressing tau-GFP in zebrafish embryos were directly imaged and traced by
time-lapse recording, in order to evaluate the neurotoxicity induced by tau-GFP proteins. Expression of tau-GFP
was observed to cause high levels of neuronal death. However, multiple signaling factors, such as Bcl2-L1, Nrf2,
and GDNF, were found to effectively protect neuronal cells expressing tau-GFP from death. Treatment with
chemical compounds that exert anti-oxidative or neurotrophic effects also resulted in a similar protective effect
and maintained human tau-GFP protein in a phosphorylated state, as detected by antibodies pT212 and AT8.
Conclusions: The novel finding of this study is that we established an expression system expressing tau-GFP in zebrafish
embryos were directly imaged and traced by time-lapse recording to evaluate the neurotoxicity induced by tau-GFP
proteins. This system may serve as an efficient in vivo imaging platform for the discovery of novel drugs against tauopathy.
Keywords: Tauopathy, Bcl2-L1, Nrf2, Neurotoxicity, GDNF, Zebrafish
Background
The axonal tau protein is a tubulin-binding protein
that plays important roles in the formation and stabil-
ity of the microtubule (MT) [1, 2]. The status of tau
phosphorylation is directly related to its biological
activity [3]. Hyperphosphorylated tau has lower
affinity for MTs, which results in destabilization of
MTs [4]. Tauopathies, a class of neurodegenerative disor-
ders, are known to link to tau aggregates [5]. Muta-
tions in the tau gene are associated with familial
forms of frontotemporal dementia with Parkinsonism
linked to chromosome-17 (FTDP-17) [6, 7]. Fronto-
temporal dementia (FTD) is an adult neurodegenerative
disorder that exhibits symptoms commonly seen in
tauopathy-associated dementia. Alzheimer’s disease (AD)
belongs to one tauopathy family, and is characterized by
the presence of intracellular neurofibrillary tangles (NFTs)
composed of paired helical filaments of tau, and extracel-
lular plaques containing beta-amyloid [8, 9].
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Truncated forms of tau protein [10] are also found in
NFTs in AD brain, suggesting that truncated tau may
predispose toward the formation of NFTs [11–14]. Trun-
cation of tau protein has been identified in human
sporadic AD [12], and proteolytic cleavage of tau has
been proposed to be an early event in the aggregation of
tau protein and formation of neurofibrillary lesions in
AD. Caspases and other proteases were found to cleave
human tau protein at discrete locations in vivo; these
sites include Asp421 [15–17] and Glu391 [10]. Purified re-
combinant tau proteins truncated after Glu391 or Asp421
(i.e., hTau-△392 or hTau-△422) aggregate easily in vitro,
resulting in more rapid fibrillization than that of intact
proteins [17, 18]. In addition, the caspase-3-cleaved
tau fragment was demonstrated to propagate the for-
mation of AD-like NFTs in a transgenic rat model
[14], corroborating the causative role of truncated tau
in AD neurodegeneration in vivo.
Human tau is encoded by the MAPT (microtubule-
associated protein tau) gene with 16 exons. In the adult
human brain, six isoforms of the tau gene, which are prod-
ucts of alternative splicing of exons 2, 3, and 10, have been
identified. Three isoforms have three tubulin-binding
domains (3R), and the other three isoforms (4R) have an
additional tubulin-binding domain encoded by exon 10
[19, 20]. Inclusion of exon 2, or exons 2 and 3, gives rise
to an additional 29 or 58 amino acids at the N-terminal
region, respectively [21]. In zebrafish, two MAPT paralo-
gous genes, mapta and maptb, have been identified [22]
and are regarded to be derived from an ancestral allele of
teleost MAPT by duplication. Spliced transcripts from
both genes indicated that isoforms of mapta encode four,
five, or six tubulin-binding repeats (4R-6R), while those of
maptb are mainly the 3R isoforms. Expression of both
genes is predominantly observed in the developing central
nervous system (CNS), suggesting that they possess essen-
tial roles in the embryonic development of the CNS.
Transgenic models such as mice (Mus musculus) or
flies (Drosophila melanogaster) with human tau genes
allow elucidation of how tau protein causes neurodegen-
eration in tauopathies. In Drosophila, induction of either
the endogenous tau or the ectopic human tau can result
in neurodegeneration tau [23, 24]. In addition, overex-
pressing human tau in Drosophila leads to a profound
disruption of neuronal function prior to the emergence
of neurodegeneration [25, 26]. These data thus suggest
that the neurotoxic effects of tau are evolutionarily
conserved.
Zebrafish (Danio rerio) has been demonstrated as
an excellent genetic model for studying vertebrate de-
velopment and diseases [27]. Taking such advantages,
a zebrafish model of tauopathy was made for expressing
human tau-GFP fusion protein under the control of a
neuronal enhancer derived from the gata2 promoter [28].
However, the neurotoxicity of the tau-GFP fusion protein
prevented the establishment of stable transgenic lines.
Another transgenic zebrafish model of tauopathy was
generated by expressing human tau using the zebrafish
enolase2 promoter [29]. Although this line could specific-
ally express human tau protein in the nervous system, no
significant tauopathy was observed at larval stages of
development. This may be due to week expression of the
enolase gene in the first 60 h post fertilization. Re-
cently, a Gal4-UAS-based zebrafish model of tauopathy
was created for expressing human Tau-P301L [30]. A
neuronal HuC promoter [31] was used to drive the
expression of this mutant 4R-tau protein. This model
recapitulates some of the most important pathological
features of tauopathies and has been adopted for drug
screening based on whole-mount antibody staining using
different anti-tau conformation antibodies. However, this
procedure is time-consuming, and direct image tracing is
difficult to perform.
In order to improve the assay of human tau in zebra-
fish, we generated a model where tau-GFP expression
and neurotoxicity could be live monitored. We found
that neuronal cells expressing tau-GFP in these models
can be readily imaged and traced to evaluate the neuro-
toxicity induced by oligomeric tau proteins. These findings
are in line with the hypothesis that tau oligomers are more
toxic than tau aggregates to neuronal cells [32, 33]. By
contrast, treatment of zebrafish embryos with gene prod-
ucts or chemical compounds that exhibit anti-apoptotic,
anti-oxidative, or neurotrophic effects could prevent the
tau-GFP-expressing neurons from death. The accessibility
of live imaging and chemical treatment in our zebrafish
model will allow screening more drugs against tauopathy.
Methods
Zebrafish care
Zebrafish embryos were raised at 28.5 °C, and different
developmental stages were determined based on the
criteria described in the Zebrafish Book [34]. All ani-
mal procedures were approved by the Academia Sinica
Institutional Animal Care and Utilization Committee
(ASIACUC) (protocol #10-12-114).
Cloning of full-length cDNAs encoding z3R-tau and
h4R-tau
Full-length cDNAs encoding z3R-tau and h4R-tau were
isolated by PCR amplification using gene-specific primers
(zTau-F, 5′-ATG GAC CAT CAG GAC CAC ATG AAT
TCT-3′ and zTau-R, 5′-CAG GCC TTG TTT AGC AAG
GGA GGC CGA-3′; hTau-F, 5′-ATG GCT GAG CCC
CGC CAG GAG-3′ and hTau-R, 5′-CAA ACC CTG
CTT GGC CAG GGA-3′) based on the sequences of
zebrafish EST clones (accession numbers EH433182 and
EH608572) or GenBank accession number BC114504.
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The cDNA encoding z3R-tau or h4R-tau was subcloned
into pHA-YUN-GFP vector to generate pCMV-z3R-tau-
GFP or pCMV-h4R-tau-GFP, respectively.
Construction of expression plasmids
Complementary DNA encoding z3R-tau-Δ260, z3R-tau-
Δ290, h4R-tau-Δ422, or h4R-tau-Δ392 was re-amplified
by PCR using primers with built-in restriction sites;
the resulting PCR products were then individually
subcloned into pHA-YUN-GFP at appropriate sites to
generate pCMV-z3R-tau-Δ260-GFP, pCMV-z3R-tau-Δ290-
GFP, pCMV-h4R-tau-Δ422-GFP, and pCMV-h4R-tau-
Δ392-GFP, respectively. To express GFP fusion proteins
in neurons, each DNA fragment encoding a GFP-fusion
protein was inserted into the corresponding sites of
pHuC-GFP plasmid to replace the GFP coding region,
thereby generating pHuC-z3R-tau-GFP, pHuC-z3R-tau-
Δ260-GFP, pHuC-z3R-tau-Δ290-GFP, pHuC-h4R-tau-GFP,
pHuC-h4R-tau-Δ422-GFP, and pHuC-h4R-tau-Δ392-GFP,
respectively. The control plasmid pHuC-GFP was previ-
ously described, and GFP genes were driven by a zebrafish
neuron-specific HuC promoter [31].
Expression plasmids pHuC-zBcl2-L1-HA-2A-mCherry,
pHuC-zNrf2-HA-2A-mCherry, pGFAP-zBDNF-HA, and
pGFAP-zGDNF-HA were constructed for co-injection with
pHuC-z3R-tau-GFP or pHuC-h4R-tau-GFP. The zBcl2-L1,
zNrf2, zBDNF, and zGDNF constructs were amplified
based on sequences from NCBI GenBank accession num-
bers NM_131807 [35], NM_182889 [36], NM_001308649
[37] and NM_131732 [38], respectively, and then sub-
cloned into pCMV-HA-2A-mCherry or pCMV-HA. The
zBcl2-HA-2A-mCherry and zNrf2-HA-2A-mCherry se-
quences were inserted into the corresponding sites of the
pHuC-GFP plasmid to replace the GFP coding region
and to generate pHuC-zBcl2-L1-HA-2A-mCherry and
pHuC-zNrf2-HA-2A-mCherry, respectively. The zBcl2-
L1 or zNrf2 and mCherry proteins can be expressed from
a single transcript by using a self-cleaving 2A peptide de-
rived from porcine teschovirus-1 (P2A; GSGATNFSLLK-
QAGDVEENPGP) [39]. The zBDNF-HA and zGDNF-HA
sequences were individually inserted into the pGFAP-GFP
plasmid to replace the GFP coding region and to gen-
erate pGFAP-zBDNF-HA and pGFAP-zGDNF-HA, re-
spectively. The control plasmid pGFAP-GFP was previously
described, and GFP genes were driven by a zebrafish glial
cell-specific GFAP promoter [40].
Microinjection of zebrafish embryos
Plasmid DNA was injected into one-cell zygotes using
a microinjection system consisting of a SZX9 stereo-
microscope (Olympus, Tokyo, Japan) and an IM300
Microinjector (Narishige, Tokyo, Japan). The concentra-
tion of all plasmid DNA used to microinject is about
500 ng/μl and the amount of all plasmid DNA injected
into zebrafish embryos is about 0.2 ng. Embryos at 24
and 48 h post-fertilization (hpf ) were observed under
an Olympus IX70-FLA inverted fluorescence microscope.
Images were taken using the SPOT system (Diagnostic
Instruments, Sterling Heights, MI).
TUNEL assay
For detection of apoptotic cells, the embryos were fixed
in 4 % PFA overnight, washed several times with PBST,
and stored in methanol at −20 °C. To perform TUNEL
assay, embryos were rehydrated with methanol/PBST
series, treated with proteinase K, and then fixed in 4 %
PFA at room temperature. Apoptotic cells were detected
by In Situ Cell Death Detection Kit (Roche Diagnostics,
Germany) according to instructions of the manufacturer.
Whole-mount immunostaining
Whole-mount immunostaining was performed following
standard protocols as previously described [41] with some
modifications. The antibodies used were as follows: mouse
anti-GFP (1E4) (1:300) (MBL, Nagoya, Japan), mouse
anti-HA (F-7) (1:100) (Santa Cruz Biotechnology, Inc.,
Santa Cruz, CA), mouse anti-human PHF-Tau (AT8)
(1:100) (Thermo Fisher Scientific, West Palm Beach, FL),
rabbit anti- Caspase-9 (Novus Biologicals, Inc., Littleton,
CO,USA), rabbit anti-Tau [pT212] (Thermo Fisher Scien-
tific), rabbit anti-GFP (1:300) (Abcam, Cambridge, UK),
Cy3-conjugated anti-mouse IgG (1:100), Cy2-conjugated
anti-mouse IgG (1:100), Cy2-conjugated anti-rabbit IgG
(1:100) and Cy3-conjugated anti-rabbit IgG (1:100)
(Jackson ImmunoResearch Laboratories, Inc., West Grove,
PA). High resolution images of the samples were captured
using a Leica SP5 X Inverted Confocal Microscope.
Western blot analysis
One hundred pHuC-h4R-tau-GFP-injected embryos or
wild-type embryos were collected at 24 hpf for inde-
pendent experiments. The sample preparation was based
on the protocols described in the Zebrafish Book [34].
Clarified lysates containing equivalent amounts of pro-
teins derived from zebrafish embryos were analyzed by
Western blotting with the following antibodies: mouse
anti-human PHF-Tau (AT8) (1:3000) (Thermo Fisher Sci-
entific), rabbit anti-GFP (1:5000) (Abcam), mouse anti-
GAPDH (1D4) (1:5000) (Novus Biologicals, Inc., Littleton,
CO,USA), HRP-conjugated AffiniPure goat anti-mouse
IgG (1:20000) (Jackson ImmunoResearch Laboratories,
Inc., West Grove, PA).
Chemical treatment
Stock solutions of DADS (10 mM) (Sigma) [42] and
Luteolin (100 mM) (Sigma) [43] were prepared in DMSO.
Zebrafish embryos injected with pHuC-h4R-tau-GFP
were incubated in water containing DMSO or the
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above compounds from 6 to 48 hpf. The working
concentration of DADS is 20 μM and the luteolin is
400 μM.
Neuronal toxicity assay
The ability of wild-type human Tau protein to induce
cell death in developing neuronal cells was investigated
using pHuC-h4R-tau-GFP. The expression construct was
injected into zebrafish embryos at the 1-cell stage. GFP-
labeled neuronal cells were observed at 24 and 48 hpf
under a fluorescence microscope. Certain GFP signals
were observed in neuronal cells of 24 hpf embryos,
before diminishing into small dots in 48 hpf embryos.
However, other GFP signals remained intact in neuronal
cells. The numbers of neurons with GFP signals in
48 hpf embryos were counted and separated into
two groups: 2 or fewer neurons (0–2) and more than
2 neurons (between 3–5).
Results
Induction of neuronal death by overexpression of
wild-type and truncated forms of human and zebrafish
tau proteins in zebrafish embryo
Truncation of Tau protein by caspases and other prote-
ases has been identified at discrete sites, including
Asp421 [15–17, 44] and Glu391 [10, 45]. Purified recom-
binant Tau proteins truncated after Glu391 or Asp421,
designated as h4R-tau-Δ392 or h4R-tau-Δ422, are prone
to aggregate in vitro, resulting in faster rates of fibrilliza-
tion than those of WT proteins [17, 18]. In addition, the
caspase-3-cleaved tau fragment was demonstrated to
exert toxic effects in cultured neural cells [16, 17, 46].
These findings prompted us to examine whether zebra-
fish Tau proteins truncated after Asp259 or Asp289 (equiva-
lent to human tau truncation at Glu391 or Asp421) can
induce neurotoxic effects. Truncated zebrafish 3R-tau pro-
teins were generated and tagged with green fluorescence
protein (GFP), and designated as z3R-Tau-Δ260-GFP or
z3R-tau-Δ290-GFP (Fig. 1a). The h4R-tau-Δ392-GFP and
h4R-tau-Δ422-GFP constructs were generated by a similar
approach. GFP was also fused to wild-type zebrafish and
human tau proteins to generate z3R-tau-GFP and h4R-
tau-GFP, respectively (Fig. 1a).
To investigate whether the truncated and wild-type
tau proteins could affect the survival of neuronal cells,
the neuronal expression of recombinant tau was driven
by a neuron-specific HuC promoter [31]. As shown in
Fig. 1b, GFP-labeled neuronal cells and axons were
observed at 24 and 48 hpf (panels a, a’, and a”) in
embryos injected with pHuC-GFP as a control. On the
other hand, while GFP-labeled neuronal cells were viable
at 24 hpf in embryos injected with z3R-tau-GFP (Fig. 1b,
panels b, b’, and b”), z3R-tau-Δ290-GFP (Fig. 1b, panels
c, c’, and c”), z3R-tau-Δ260-GFP (Fig. 1b, panels d, d’,
and d”), h4R-tau-GFP (Fig. 1b, panels e, e’, and e”), h4R-
tau-Δ422-GFP (Fig. 1b, panels f, f ’, and f”), or h4R-tau-
Δ392-GFP (Fig. 1b, panels g, g’, and g”), such neurons
were dramatically lost at 48 hpf (Fig. 1b, panels b”-g”).
Some GFP signals readily dissipated into small puncta
(panels d’, e’, f ’, and g’). With the aid of time-lapse re-
cording, five GFP-labeled neuronal cells in embryos
injected with h4R-tau-GFP were traced (Fig. 1c). Puncta
formation was first observed in neuron E at 25 hpf,
followed by neuron C at 26 hpf, neuron B at 27 hpf, and
neuron A at 28 hpf. Interestingly, only neuron D
remained intact during the recording time, suggesting
that only this neuron may have survived. In order to
distinguish whether the puncta formation is due to cell
death, not only due to reduced GFP expression, we
performed TUNEL staining and immunostaining with
anti-caspase 9 as shown in Fig. 1d. These data indiated
that expression of tau-GFP induced neuronal death
through apoptosis.
Expression of zebrafish Bcl2-L1 can prevent induction of
neuronal death by overexpression of human 4R-tau and
zebrafish 3R-tau
We proceeded to investigate whether certain signaling
factors can prevent neuronal death induced by overex-
pression of wild-type human and zebrafish tau proteins.
We first tested the effect of anti-apoptotic factor, Bcl2-L1,
which has been shown to regulate a caspase-3-dependent
apoptotic mechanism during thyroid development in zeb-
rafish [35]. The C-terminal end of Bcl2-L1 was tagged
with HA peptide for detection of protein production. Both
Bcl2-L1-HA and another mCherry red fluorescence pro-
tein, a variant of the Discosoma red (DsRed) protein [47],
were co-expressed from a single transcript by the use of a
self-cleaving 2A peptide [39]. Thus, the expression level of
Bcl2-L1-HA and mCherry protein is equal.
We demonstrated that GFP-labeled neuronal cells and
axons could be observed at 24 and 48 hpf in embryos
co-injected with either pHuC-zBcl2-L1-HA-2A-mCherry
plus pHuC-z3R-tau-GFP (Fig. 2a, panels a, a’, a”) or
pHuC-zBcl2-L1-HA-2A-mCherry plus pHuC-h4R-tau-
GFP (Fig. 2a, panels b, b’, and b”). The protection effect
of zBcl2-L1 was presented in panel e to show higher
percentage, 69 % or 66 % of zebrafish embryos express-
ing zBcl2-L1 with more neuronal cells, compared to
21 % or 18 % without zBcl2-L1. These data suggested
that overexpression of Bcl2-L1 in neurons can prevent
neurotoxicity induced by zebrafish or human tau-GFP.
The viable GFP-labeled neuron at 48 hpf not only dis-
played mCherry red fluorescence (Fig. 2b, panels a and
a’), but was also immunoreactive to antibodies pT212
(Fig. 2c, panel b) and AT8 (Fig. 2c, panel b’). Antibody
AT8 recognizes phosphorylated paired helical filament
of human tau protein at both serine 202 and threonine
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Fig. 1 Overexpression of human and zebrafish tau proteins in zebrafish embryo resulted in neuronal death. a Schematic diagrams of each
expression construct containing either wild-type or truncated forms of human and zebrafish Tau tagged with green fluorescence protein (GFP).
Each expression construct was driven by the HuC promoter. The black bar represents one repeat of tubulin binding domain. The wild-type human
and zebrafish tau proteins contain four and three repeats, respectively. b Each expression construct was microinjected into zebrafish embryos at
the one-cell stage. Zebrafish embryos with GFP signals at 24 to 48 hpf were selected for image analysis. Embryos are shown in the lateral view
with the anterior to the left and dorsal to the top. The boxed region of each panel (a-g) is enlarged (a’-g”) to show the GFP-labeled neuronal cells
in 24 to 48 hpf embryos from the lateral view. Scale bars: 100 μm. c The five GFP-labeled neuronal cells in embryos injected with pHuC-h4R-tau-
GFP were traced with the aid of time-lapse recording. Puncta formation was observed in neuron E at 25 hpf, neuron C at 26 hpf, neuron B at
27 hpf, and neuron A at 28 hpf. Scale bars: 100 μm. d TUNEL staining (panel a) and double immunostaining of zebrafish embryos expressing
h4R-tau-GFP at different developmental stages was performed using polyclonal antibody against Caspase 9 and monoclonal antibody against
GFP (panel b). Scale bar: 50 μm
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Fig. 2 Zebrafish Bcl2-L1 overexpression prevented human 4R-tau-GFP and zebrafish 3R-tau-GFP induced Neuronal death. a GFP-labeled neuronal
cells and axons were observed at 24 and 48 hpf in embryos co-injected with pHuC-zBcl2-L1-HA-2A-mCherry and pHuC-z3R-tau-GFP (b) or pHuC-
h4R-tau-GFP (d). For comparison, embryos co-injected with pHuC-mCherry (panels a and c) were used as the control. The boxed regions are
enlarged (a’-d”) to show the GFP-labeled neuronal cells in 24 and 48 hpf embryos from the lateral view. Scale bars: 100 μm. The protection effect
of zBcl2-L1 against neuronal death by human tau-GFP or zebrafish tau-GFP was presented in panel e to show higher percentage, 69 % and 66 %
of zebrafish embryos expressing zBcl2-L1 with more neuronal cells, compared to 21 % and 18 % without zBcl2-L1. b GFP signals (panel a) and
mCherry signals (panel a’) in neuronal cells and axons in embryos co-injected with pHuC-h4R-tau-GFP and pHuC-zBcl2-L1-HA-2A-mCherry were
colocalized (panel a”). Scale bar: 50 μm. c Double immunostaining of h4R-tau-GFP (GFP antibody, panel a) and Bcl2-L1-HA (HA antibody, panel a’)
in spinal cord neurons of the aforementioned zebrafish embryos. The phosphorylation state of h4R-tau-GFP was detected using antibody pT212
(panel b) and antibody AT8 (panel b’). Embryos are shown from the lateral view with the anterior to the left and dorsal to the top. Scale bar:
50 μm. d Double immunostaining of zebrafish embryos expressing h4R-tau-GFP at different developmental stages was performed using poly-
clonal antibody against GFP and monoclonal antibody AT8. Scale bar: 50 μm. e Western blot analysis of total protein extract of zebrafish embryos
expressing h4R-tau-GFP at 24 hpf was performed using polyclonal antibody against GFP and monoclonal antibody AT8
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205. Antibody pT212 was used to detect specific phosphor-
ylation of tau at T212, which has been proposed to play im-
portant roles in self-assembly of human tau protein.
To investigate the phosphorylation status of neuronal
cells expressing only h4R-tau-GFP, we collected injected
embryos at different time to perform double immuno-
staining. As shown in Fig. 2d, the injected embryo at 24
hpf expressed tau-GFP with positive reaction to antibody
AT8 (panel a’). In 28 hpf embryo, the puncta was
observed with positive signal to both GFP and AT8
(panels b, b’ and b”). The remaining neuronal cell at 48
hpf expressed tau-GFP with positive signal to AT8
(panel c’). We also collected injected embryos at 24 hpf
to perform Western blot analysis as shown in Fig. 2e.
Monomeric and dimeric forms of tau-GFP were detected
with positive reaction to antibody AT8.
Taken together, our data demonstrate that overexpression
of Bcl2-L1 in neurons can effectively suppress the neuro-
toxicity induced by tau-GFP aggregates without disrupting
the formation of phosphorylated paired helical filaments.
Expression of zebrafish Nrf2 can prevent neuronal
death induced by overexpression of human 4R-tau and
zebrafish 3R-tau
Nuclear factor erythroid 2-related factor 2 (Nrf2) has been
shown to be an important transcription factor in the
defense against oxidative stress. Nucleus-localized Nrf2
binds to a conserved DNA motif called antioxidant re-
sponse elements (ARE) to initiate the transcription of cyto-
protective genes (phase II genes) [48]. Thus, the Nrf2-ARE
pathway controls the majority of antioxidant pathways, in-
cluding the synthesis of glutathione (GSH) and the expres-
sion of heme oxygenase-1 (HO-1). Activation of the Nrf2
−ARE pathway has been proposed to be a promising
therapeutic approach for the treatment of neurodegenera-
tive disorders [49, 50]. In addition, Nrf2 was recently
identified as a possible target for AD treatment, due
to its anti-oxidative abilities against Aβ-mediated
neurotoxicity in vitro [51]. These results prompted us
to investigate whether activation of anti-oxidative signal-
ing can also suppress neurotoxicity elicited by overexpres-
sion of tau-GFP. Here, the C-terminal end of Nrf2 was
tagged with HA peptide for detection, and Nrf2-HA was
co-transcribed with mCherry (the two coding regions
were linked with a sequence encoding a self-cleaving 2A
peptide). Zebrafish embryos were co-injected with pHuC-
zNrf2-HA-2A-mCherry and either pHuC-z3R-tau-GFP
(Fig. 3a, panels a, a’, a”) or pHuC-h4R-tau-GFP (Fig. 3a,
panels b, b’, and b”) at the 1-cell stage; GFP-labeled neur-
onal cells and axons were then imaged at 24 and 48 hpf.
The viable GFP-labeled neuron at 48 hpf not only dis-
played mCherry-emitted red fluorescence (Fig. 3b, panels
a and a’), but was also immunoreactive to antibodies
pT212 (Fig. 3c, panel b) and AT8 (Fig. 3c, panel b’). These
data clearly indicate that overexpression of Nrf2 can pro-
tect against tau-GFP-elicited neurotoxicity downstream of
tau-GFP hyperphosphorylation and aggregation.
Neuronal death by overexpression of human 4R-tau
and zebrafish 3R-tau can be rescued by expression of
zebrafish GDNF
Neurotrophins (NTs) are important for the survival and
maintenance of specific neuronal populations in the brain.
These NTs in mammals include nerve growth factor
(NGF), brain-derived neurotrophic factor (BDNF),
neurotrophin-3 (NT-3), and NT-4/5 [52, 53]. BDNF
deficiency has been implicated in the pathogenesis of Hun-
tington's disease (HD) [54, 55]. Glial cell-derived neuro-
trophic factor (GDNF) is another potent NT for a variety of
neuronal populations [56]. Recently, it has been shown to
have therapeutic potential for neurodegenerative disorders,
including AD [57] and Parkinson disease (PD) [58].
Here, we further investigated whether certain NTs can
prevent neuronal death induced by overexpression of wild-
type human and zebrafish tau proteins. The C-terminal
ends of BDNF [59] and GDNF [60] were tagged with HA
peptide for easy detection of protein production. We
expressed BDNF-HA or GDNF-HA under the control of a
glia-specific glial fibrillary acidic protein (GFAP) gene pro-
moter [40] to examine whether these proteins are able to
promote the survival of neuronal cells expressing human
and zebrafish tau-GFP proteins. Consistent with the re-
ported expression profile of GFAP in a transgenic zebrafish
model [40], zebrafish embryos that were co-injected with
pGFAP-zGDNF-HA and either pHuC-z3R-tau-GFP (Fig. 4a,
panels b, b’, b”) or pHuC-h4R-tau-GFP (Fig. 4a, panels d, d’,
and d”) contained GFP-labeled neuronal cells and axons at
24 and 48 hpf. The protection effect of GDNF against neur-
onal death induced by human tau-GFP or zebrafish tau-
GFP was presented in panel e to show higher percentage,
55 % or 53 % of zebrafish embryos expressing GDNF with
more neuronal cells, compared to 20 % or 19 % without
GDNF. The viable GFP-labeled neuron at 48 hpf not only
displayed immunoreactivity to HA (Fig. 4b, panels a and
a’), but also showed positive immunoreactivity to antibodies
pT212 (Fig. 4b, panel b) and AT8 (Fig. 4b, panel b’). These
data indicate that zGDNF-HA can possibly bind to GDNF
family receptor subtype α1 (GFRα1) to induce neuroprotec-
tive effects in tau-GFP-expressing neurons, without inter-
fering with the hyperphosphorylation and aggregation of
tau-GFP protein. In contrast, BDNF-HA expression in zeb-
rafish embryos (Fig. 4a, panels a and c) was not sufficient to
suppress tauopathy-elicited neurotoxicity.
Treatment with DADS and luteolin can prevent neuronal
death induced by overexpression of human 4R-tau
To further confirm the hypothesis that augmentation of
anti-oxidative pathways can suppress tauopathy-induced
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Fig. 3 Zebrafish Nrf2 overexpression prevented human 4R-tau-GFP and zebrafish 3R-tau-GFP induced Neuronal death. a GFP-labeled neuronal
cells and axons were observed at 24 and 48 hpf in embryos co-injected with pHuC-zNrf2-HA-2A-mCherry and pHuC-z3R-tau-GFP (b) or pHuC-
h4R-tau-GFP (d). For comparison, embryos co-injected with pHuC-mCherry (panels a and c) were used as the control. The boxed regions are
enlarged (a’-d”) to show the GFP-labeled neuronal cells in 24 and 48 hpf embryos from the lateral view. Scale bars: 100 μm. The protection effect
of zNrf2 against neuronal death induced by human tau-GFP or zebrafish tau-GFP was presented in panel e to show higher percentage, 58 % and
55 % of zebrafish embryos expressing zNrf2 with more neuronal cells, compared to 19 % and 17 % without zNrf2. b GFP signals (panel a) and
mCherry signals (panel a’) in neuronal cells and axons in embryos co-injected with pHuC-h4R-tau-GFP and pHuC-zNrf2-HA-2A-mCherry were
colocalized (panel a”). Scale bar: 50 μm. c Double immunostaining of h4R-tau-GFP (GFP antibody) and zNrf2-HA (HA antibody, panel a’) in spinal
cord neurons of the aforementioned zebrafish embryos. The phosphorylation state of h4R-tau-GFP was detected using antibody pT212 (panel b)
and antibody AT8 (panel b’). Scale bar: 50 μm
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neurotoxicity, we examined neuronal survival in zebra-
fish embryos co-injected with pHuC-h4R-Tau-GFP and
pHuC-zBcl2-L1-HA-2A-mCherry, pHuC-zNrf2-HA-2A-
mCherry, pGFAP-zGDNF-HA, or pHuC-mCherry at 48
hpf. Viable GFP-positive neurons in individual embryos
were counted. Injected zebrafish embryos at 48 hpf were
categorized into two groups: those with 2 or fewer viable
GFP-positive neurons per embryo (0 ~ 2) and those with
more than 2 GFP-positive neurons per embryo (3 ~ 5).
We found that 82 % of embryos injected with pHuC-
h4R-Tau-GFP had only 0–2 GFP-positive neurons, while
the other 18 % contained more than 2 GFP-positive neu-
rons (Fig. 5a, panel e). We observed that co-expression
of Bcl2-L1, Nrf2, or GDNF significantly promoted the
survival of GFP-positive neurons in embryos injected
with pHuC-h4R-Tau-GFP, increasing the percentage of
embryos containing more than 2 GFP-positive neurons
to 66 %, 55 %, and 53 %, respectively (Fig. 5a, panel e).
Fig. 4 Zebrafish GDNF overexpression prevented human 4R-tau-GFP and zebrafish 3R-tau-GFP induced Neuronal death. a GFP-labeled neuronal
cells and axons were observed at 24 and 48 hpf in embryos co-injected with pGFAP-zGDNF-HA and pHuC-z3R-tau-GFP (b) or pHuC-h4R-tau-GFP
(d). For comparison, embryos co-injected with pGFAP-zBDNF-HA (panels a and c) were used as the control. The boxed regions are enlarged
(a’-d”) to show the GFP-labeled neuronal cells in 24 to 48 hpf embryos from the lateral view. Scale bars: 100 μm. The protection effect of GDNF
against neuronal death induced by human tau-GFP or zebrafish tau-GFP was presented in panel e to show higher percentage, 55 % and 53 %
of zebrafish embryos expressing GDNF with more neuronal cells, compared to 20 % and 19 % without GDNF. b Double immunostaining of
h4R-tau-GFP (GFP antibody, panel a) and GDNF-HA (HA antibody, panel a’) in spinal cord neurons of the aforementioned zebrafish embryos.
The phosphorylation state of h4R-tau-GFP was detected using antibody pT212 (panel b) and antibody AT8 (panel b’). Scale bar: 50 μm
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Fig. 5 (See legend on next page.)
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Consistent with these findings, tau-GFP-expressing
embryos that were treated with diallyl-disulfide (DADS)
or luteolin also exhibited significant enhancement of
neuronal survival, increasing the percentage of embryos
containing more than 2 GFP-positive neurons to 52 %
and 45 %, respectively (Fig. 5b, panel d). DADS has been
reported to activate the Nrf-2/HO-1 pathway [42], while
luteolin has been identified to be highly active in indu-
cing the synthesis and secretion of neurotrophic factors,
including GDNF [43]. However, luteolin also has been
identified to provide neuroprotective effects, possibly
through activation of the Nrf2–ARE pathway [61]. These
data suggest that chemical stimulation of anti-oxidative
signaling by DADS or luteolin can recapitulate the
neuroprotective effects induced by the overexpression of
Nrf2 (Fig. 5b, panel d versus Fig. 5a, panel e). Immuno-
staining of tau-expressing zebrafish embryos with AT8
and pT212 antibodies further confirmed that DADS-
induced and luteolin-induced stimulation of anti-oxidative
signaling can suppress neurotoxicity despite the presence
of hyperphosphorylated and aggregated tau (Fig. 5c, panel
a-b”). Together, our present findings strongly suggest that
the newly established zebrafish models of tauopathy are
highly conducive to high-content live imaging analysis,
thereby facilitating the discovery of novel anti-tauopathy
drugs and therapeutics against AD.
Discussion
In this study, a transient expression system was estab-
lished to express GFP fusion proteins of either zebrafish
3R-tau or human 4R-tau under the control of a neuron-
specific HuC promoter [31]. In this system, approxi-
mately 10 neuronal cells expressing tau-GFP in zebrafish
embryos were directly imaged and traced by time-lapse
recording to evaluate the neurotoxicity induced by tau-
GFP proteins. As shown in Fig. 1c, five GFP-labeled
neuronal cells in embryos injected with pHuC-h4R-tau-
GFP were traced from 25 hpf to 28 hpf, but only one
neuron appeared to be intact. This observation is con-
sistent with the finding that 81 % of embryos injected
with pHuC-h4R-Tau-GFP had only 0–2 neurons (Fig. 5a,
panel e). It is also consistent with an earlier proposal
that tau oligomers, rather than tau aggregates, are more
toxic to the cell [32, 33].
Truncation of tau protein by caspases and other prote-
ases has been previously reported; purified recombinant
human tau proteins truncated after Glu391 or Asp421
(equivalent to h4R-tau-△392 and h4R-tau-△422 in this
study) are prone to aggregation in vitro, resulting in fas-
ter rates of fibrillization [17, 18]. Initially, we examined
whether forms of zebrafish tau protein truncated after
Asp259 or Asp289 (equivalent to human tau truncation at
Glu391 or Asp421) elicit more neurotoxic effects than that
of wild-type. Wild-type human tau-GFP exerts a strong
neurotoxic effect (Fig. 1c; Fig. 5a, panel e); our data
(Fig. 1b) indicates that truncated forms of either zebra-
fish or human tau protein induce similar neurotoxic
effects to that of wild-type. Nrf2 has been shown to play
pivotal roles in the defense against oxidative stress. In
normal cells, the protein Kelch-like ECH-associated
protein 1 (Keap1) forms a complex with Nrf2 through
its active sulfhydryl group of cysteine residues. This
association anchors Nrf2 in cytosol and directs it to
ubiquitin-mediated proteasome degradation [62]. Elec-
trophilic agents, such as gracilins [63] and DADS [42],
can modify Keap1 to prevent it from targeting Nrf2 for
degradation, thereby promoting Nrf2 stabilization and
subsequent activation of Nrf2 target genes. Nrf2 was
recently identified as a possible target for AD treatment,
due to its antioxidative protective abilities against Aβ-
mediated toxicity in vitro [51]. Dimethyl fumarate (DMF)
is another synthetic Nrf2 activator that has been approved
by the FDA for treatment of multiple sclerosis [64]. In this
study, Nrf2 overexpression and DADS treatment were
shown to effectively protect neuronal cells expressing
tau-GFP from death. Thus, our expression system could
be used to evaluate the therapeutic potential of other
electrophilic agents, such as gracilins and DMF.
GDNF was first identified as a trophic factor for em-
bryonic midbrain dopaminergic neurons [65], and subse-
quently found to act as a potent NT for a variety of
neuronal populations [56], including peripheral neurons
such as enteric, sympathetic, and parasympathetic neu-
rons [66]. For intracellular signaling, GDNF first binds
to glycosylphosphatidyl inositol (GPI)-anchored GDNF-
(See figure on previous page.)
Fig. 5 DADS and luteolin treatment prevent neuronal death induced by overexpression of h4R-tau-GFP. a In pHuC-h4R-Tau-GFP-injected embryos,
which respectively co-expressed Bcl2-L1 (panel a), Nrf2 (panel b), or GDNF (panel c), there are more neuronal cells survived. Statistical analysis
(panel e) represents the quantitative results of zebrafish embryos respectively co-expressing Bcl2-L1 or Nrf2 or GDNF to have higher percentage
of more neuronal cells compared to the control. The n value is indicated. b Numbers of zebrafish embryos with more neuronal cells were counted as
described above for pHuC-h4R-Tau-GFP-injected embryos treated with DADS (diallyl-disulfide) (panel a) and luteolin (panel b). Statistical
analysis (panel e) was presented similarly as described above to show that pHuC-h4R-Tau-GFP-injected embryos treated with DADS or
luteolin have higher percentage of more neuronal cells compared to the control. c The effects of DADS and luteolin treatment on h4R-
tau-GFP-induced neuronal death were confirmed by double immunostaining of GFP-labeled neurons at 48 hpf. The phosphorylation state
of h4R-tau-GFP was detected by antibody pT212 (panels a and b) and antibody AT8 (panels a’ and b’). Embryos are shown from the
lateral view with the anterior to the left and dorsal to the top. Scale bar: 50 μm
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family receptor α1 (GFRα1), and then recruits a trans-
membrane receptor RET [67] to form a complex that
enables autophosphorylation of RET, which in turn initi-
ates a number of downstream intracellular pathways [68].
However, GDNF can also signal independently of Ret
through neural cell adhesion molecule (NCAM) or inter-
acting with heparin sulphate glycosaminoglycans [69].
GDNF is increasingly recognized to be a potent neuro-
trophic factor with therapeutic potential against neurode-
generative diseases, including AD. Recombinant lentiviral
vectors were previously used to overexpress the GDNF
gene in hippocampal astrocytes of 3xTg-AD mice, reveal-
ing that GDNF exerts neuroprotective effects in this
AD experimental model [70]. In the present study,
zebrafish GDNF was expressed under a glia-specific
GFAP gene promoter [40], which conferred neuroprotec-
tion against tau-GFP-induced neuronal death (Fig. 4a and
b). In addition to the therapeutic potential for AD [57]
and PD [58], this is the first report to indicate that GDNF
has therapeutic potential for treating tau-induced neur-
onal death. In addition, chemical compounds have been
shown to have the potential to stimulate synthesis and
secretion of BDNF and GDNF in cultured astrocytes [71].
Although luteolin has been identified to be highly active at
inducing the synthesis and secretion of neurotrophic
factors, including GDNF [43], luteolin has also been
identified to provide neuroprotective effects, possibly
through activation of the Nrf2–ARE pathway [61].
Conclusions
In conclusion, our zebrafish tauopathy models can be
subjected to high-content live imaging analysis, making
them an ideal platform with which to identify anti-
tauopathy drugs and treatments against AD.
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